AVMAPKI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Avmapki, and what generic alternatives are available?
Avmapki is a drug marketed by Verastem Inc and is included in one NDA. There are seven patents protecting this drug.
The generic ingredient in AVMAPKI is avutometinib potassium; defactinib hydrochloride. One supplier is listed for this compound. Additional details are available on the avutometinib potassium; defactinib hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Avmapki
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AVMAPKI?
- What are the global sales for AVMAPKI?
- What is Average Wholesale Price for AVMAPKI?
Summary for AVMAPKI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | AVMAPKI at DailyMed |
US Patents and Regulatory Information for AVMAPKI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verastem Inc | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) | avutometinib potassium; defactinib hydrochloride | CAPSULE, TABLET;ORAL | 219616-001 | May 8, 2025 | RX | Yes | Yes | 11,873,296 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Verastem Inc | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) | avutometinib potassium; defactinib hydrochloride | CAPSULE, TABLET;ORAL | 219616-001 | May 8, 2025 | RX | Yes | Yes | 12,509,450 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Verastem Inc | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) | avutometinib potassium; defactinib hydrochloride | CAPSULE, TABLET;ORAL | 219616-001 | May 8, 2025 | RX | Yes | Yes | 7,928,109 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
